Document Type : Original Article


Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran


COVID-19 and autoimmune rheumatic diseases has been an interesting issue since the beginning of the COVID-19 pandemic. This survey was designed to study COVID-19 reinfection in autoimmune rheumatic patients and to find possible risk factors for reinfection related to autoimmune rheumatic diseases or their medications. In this cross-sectional survey, autoimmune rheumatic patients attending rheumatology clinics were interviewed to find rheumatic patients who had been infected by COVID-19. A group of patients who had been infected by COVID-19 just for one time and another group who had never been infected by COVID-19, were considered as control groups. Demographic and clinical characteristics of the three groups were compared. We found 15 patients (mean age: 45.33) who had been infected by COVID-19 two times. Rheumatoid arthritis was the most common disease (33.33%) and prednisolone was the most commonly used medication among these patients (80%). The mean interval between first and second infections was 8.53 months. We detected no significant differences for age, sex, type of autoimmune rheumatic disease, medications and comorbidities between our three group. Neither the type of autoimmune rheumatic disease, nor the type of medication used to treat it, was a risk factor for COVID-19 reinfection.


Main Subjects